Cost-benefit of outcome adjudication in nine randomised stroke trials.


Journal

Clinical trials (London, England)
ISSN: 1740-7753
Titre abrégé: Clin Trials
Pays: England
ID NLM: 101197451

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 12 7 2020
medline: 14 1 2021
entrez: 12 7 2020
Statut: ppublish

Résumé

Central adjudication of outcomes is common for randomised trials and should control for differential misclassification. However, few studies have estimated the cost of the adjudication process. We estimated the cost of adjudicating the primary outcome in nine randomised stroke trials (25,436 participants). The costs included adjudicators' time, direct payments to adjudicators, and co-ordinating centre costs (e.g. uploading cranial scans and general set-up costs). The number of events corrected after adjudication was our measure of benefit. We calculated cost per corrected event for each trial and in total. The primary outcome in all nine trials was either stroke or a composite that included stroke. In total, the adjudication process associated with this primary outcome cost in excess of £100,000 for a third of the trials (3/9). Mean cost per event corrected by adjudication was £2295.10 (SD: £1482.42). Central adjudication is a time-consuming and potentially costly process. These costs need to be considered when designing a trial and should be evaluated alongside the potential benefits adjudication brings to determine whether they outweigh this expense.

Sections du résumé

BACKGROUND
Central adjudication of outcomes is common for randomised trials and should control for differential misclassification. However, few studies have estimated the cost of the adjudication process.
METHODS
We estimated the cost of adjudicating the primary outcome in nine randomised stroke trials (25,436 participants). The costs included adjudicators' time, direct payments to adjudicators, and co-ordinating centre costs (e.g. uploading cranial scans and general set-up costs). The number of events corrected after adjudication was our measure of benefit. We calculated cost per corrected event for each trial and in total.
RESULTS
The primary outcome in all nine trials was either stroke or a composite that included stroke. In total, the adjudication process associated with this primary outcome cost in excess of £100,000 for a third of the trials (3/9). Mean cost per event corrected by adjudication was £2295.10 (SD: £1482.42).
CONCLUSIONS
Central adjudication is a time-consuming and potentially costly process. These costs need to be considered when designing a trial and should be evaluated alongside the potential benefits adjudication brings to determine whether they outweigh this expense.

Identifiants

pubmed: 32650688
doi: 10.1177/1740774520939231
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

576-580

Subventions

Organisme : Medical Research Council
ID : MC_UU_12023/24
Pays : United Kingdom

Auteurs

Peter J Godolphin (PJ)

Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.
MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK.

Philip M Bath (PM)

Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.

Ale Algra (A)

Department of Neurology and Neurosurgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Eivind Berge (E)

Department of Internal Medicine, Oslo University Hospital, Oslo, Norway.

John Chalmers (J)

The George Institute for Global Health, University of NSW, Sydney, NSW, Australia.

Misha Eliasziw (M)

Department of Public Health and Community Medicine, Tufts University, Boston, MA, USA.

Graeme J Hankey (GJ)

Medical School, The University of Western Australia, Perth, WA, Australia.

Naohisa Hosomi (N)

Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.

Annamarei Ranta (A)

University of Otago, Wellington, New Zealand.

Christian Weimar (C)

Universitätsklinikum Essen, Klinik für Neurologie, Hufelandstr, Essen, Germany.

Lisa J Woodhouse (LJ)

Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.

Alan A Montgomery (AA)

Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH